AbbVie Inc. (ABBV) announced on Friday that the European Commission has granted approval for Skyrizi to treat adults with ulcerative colitis.
Ulcerative colitis, a subset of inflammatory bowel disease (IBD), results in inflammation of the lining of the large intestine and rectum.
This approval follows the successful outcomes of two phase studies, the INSPIRE induction trial and the COMMAND maintenance trial, where Skyrizi met the primary endpoint of achieving clinical remission.
Skyrizi has already received approval in the United States for the treatment of ulcerative colitis, Crohn's disease, plaque psoriasis, and psoriatic arthritis.
